Institution identification

PURI

https://redirect.ema.europa.eu/resource/104464

Institution ID

104464

Institution full name and acronym

Data Analytic Center (DAC), Danish Medicine Agency

Institution countries

Denmark

Type of institution

EU Institution/Body/Agency

ENCePP partner

Yes
Institution description
DAC is the Data Analytics Centre of the Danish Medicines Agency located in Copenhagen,Denmark. DAC works to transform information and data on medicine and medicine devices into knowledge that can benefit the citizens. DAC enables the Danish Medicines Agency to offer new types of scientific advice to the pharmaceutical companies on the development of new medicines,including medicines for people with rare diseases. DAC is also developing new methods for optimized real time drug safety surveillance. DAC employs specialist from a wide range of different professional backgrounds. Experts within pharmaceutical science,data science,public health science,political science and biostatistics are just some of the resources that DAC’s has at its disposal. DAC will also take part in Ph.D. and postdoc projects.
Institution details
Experience with collecting data directly from individual patients or respondents:
No
Interest in carrying out research that is funded by pharmaceutical companies:
No

Contact

Studies conducted by the institution

A before and after, cross-sectional survey to evaluate the effectiveness of risk minimisation measures to minimise the risk of hospital-acquired hyponatraemia
Association between COVID-19 vaccines and paediatric safety outcomes in children and adolescents aged 5-19 years in the Nordic countries: Myocarditis, pericarditis and thromboembolic events
Brand-specific influenza vaccine effectiveness in the Nordic countries
Comparative effectiveness of heterologous and homologous primary- and booster SARS-CoV-2 vaccination schedules in the Nordic countries
Effectiveness of monovalent XBB.1.5-containing Covid-19 mRNA vaccines in the Nordic countries
Impact of regulatory interventions to restrict the combined use of renin-angiotensin system-acting agents in Denmark: interrupted time series analysis
Use cases for development, optimisation and implementation of artificial intelligence methods for real world data analyses in regulatory decision-making and health technology assessment along the product lifecycle (Real4Reg)